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The present trial investigated the eﬃcacy of immunotherapy with interferon-gamma (IFN-γ) in the treatment of sulfur mustard
(SM)-induced chronic skin complications. Forty subjects who were suﬀering from chronic skin complications of SM and were
diagnosed to have severe atopic dermatitis, were assigned to IFN-γ (50μg/m2) subcutaneously three times per week (n = 20) or
betamethasone valerate topical cream 0.1% (n = 20) every night for 30 days. Extent and intensity of cutaneous complications
was evaluated using scoring atopic dermatitis (SCORAD) index, and quality of life using dermatology life quality index (DLQI) at
baselineandattheendoftrial.SCORAD-AandSCORAD-BscoresweresigniﬁcantlydecreasedinbothIFN-γ andbetamethasone.
However, SCORAD-Cscorewas decreased only inthe IFN-γ group.Thereweresigniﬁcantreductionsinoverallaswell asobjective
SCORAD scores in both groups. As for the magnitude of changes, treatment with IFN-γ was associated with greater reductions
in overall, objective and segmented SCORAD scores compared to betamethasone. DLQI reduction was found to be signiﬁcantly
greater in the IFN-γ group. Promising improvements in quality life and clinical symptoms that was observed in the present study
suggest the application of IFN-γ as an eﬀective therapy for the management of SM-induced chronic skin complications.
1.Introduction
Sulfur mustard (bis-(2-chloroethyl) sulﬁde; SM) is an alky-
lating chemical warfare agent which possesses potent muta-
genic, carcinogenic, cytotoxic, and blistering properties [1].
Due to its powerful alkylating nature [2, 3], SM is capable
of reacting with multiple vital biomolecules such as lipids,
proteins, and DNA, thereby leading to the impairment of
severalbodyorgansimmediatelyafterexposure[4,5].Skinis
among the primary targets of SM which, due to its high pen-
etrability and high surface area, undergoes the most severe
damage [6].
Cutaneous complications of SM are not limited to the
acute phase but late complications may be present even 15–
20 years post exposure. These chronic complications have
been repeatedly reported in Iranian patients and shown to
signiﬁcantly aﬀect the quality of life [7–9]. The severity of
cutaneous complications is a function of dose and duration
of SM exposure [10].
During Iraq-Iran war (1983–88), SM was used against
Iranian veterans and civilians for several times rendering
about100.000Iranianschemicallyinjuredofwhomaconsid-
erable number are still suﬀering from chronic complications
[7, 8, 11]. Chronic skin complications of SM include2 The Scientiﬁc World Journal
pruritus (being the most frequent with an incidence of 70–
90%), burning sensation, pain erythema, xerosis, hyper-
and hypopigmentation, and scarring, atrophy [8, 12–14].
These chronic complications have been repeatedly reported
in Iranian patients even 15–20 years post exposure and
shown to signiﬁcantly aﬀect the quality of life [8, 9, 12–14].
In most occasions, SM-induced chronic skin complica-
tions are in the form of atopic dermatitis (AD). AD is a
common and chronic inﬂammatory skin disorder which is
characterized by eczematous lesions, erythema, xerosis, and
severe pruritus. So far, multiple factors have been identiﬁed
as etiologies of AD such as allergy, climatic conditions,
microbial infections, and epidermal dysfunction. However,
immune imbalance is regarded as the major pathomecha-
nismofAD[15].Impairedcellularimmunity,reducedIFN-γ
and elevated IgE, interleukin-4 (IL-4), and IL-13 are among
the frequent immunological features observed in AD. The
constellation of these imbalances increases the susceptibility
of patient to viral and fungal infections [16].
IFN-γ, also known as type II interferon, is a cytokine
which is critically involved in the innate as well as adaptive
immunity. IFN-γ is produced by Th1 cells, cytotoxic T cells,
and NK cells, and it has antiviral, antibacterial, antipro-
liferative, and immunomodulatory properties [17]. As a
cytokine being markedly decreased in AD, the therapeutic
eﬀectiveness of IFN-γ in AD has been investigated by a
number of trials [18–20]. The results have consistently
conﬁrmed the eﬃcacy and safety of IFN-γ for AD at both
short- and long-term use. However, IFN-γ has not yet
been tested in the alleviation of SM-induced AD symptoms.
CurrentstrategiesforthecontrolofSM-inducedchronicskin
complications are mainly symptomatic and limited to top-
ical corticosteroids, antihistamines, and local moisturizers.
Regarding the signiﬁcant impact of these complications—in
particular pruritus—on patients’ daily functioning, sleeping,
and quality of life [21], there is an urgent demand for
safe and eﬀective drugs to be used against SM-induced AD
[22, 23]. To this end, the present trial sought to investigate
for the ﬁrst time the eﬃcacy and safety of immunotherapy
with IFN-γ in the treatment of SM-induced chronic skin
complications.
2. Methods
2.1. Participants. Included subjects were chemically injured
patients who were suﬀering from chronic skin complications
of SM and were diagnosed to have severe AD. Patients
were excluded if they had a SCORAD score <50, received
IFN-γ before the initiation of trial, or had history of
diabetes mellitus, coagulopathy, myelosuppression, or any
psychological, central nervous system, hepatic, renal, car-
diovascular, thyroid, pulmonary, and autoimmune disorder.
T h e s es u b j e c t sw e r ee x p o s e dt oS Ms o m e2 0y e a r sa g oa n d
are registered in our center, have medical histories and
documents, and periodically visited in the center. Based
on previous documents, dermatologic examination in the
present trial, and their self report in the study questionnaire,
these subjects did not have a history of AD, vitiligo,
pemphigus, psoriasis, and contact dermatitis. Regarding the
known potent dermatotoxic eﬀects of sulfur mustard on the
skin, it is evident that the cutaneous complications of these
subjects are secondary to the mustard exposure.
2.2. Design. This investigation was a randomized clinical
trial which was performed in the Baqiyatallah Hospital
(Tehran, Iran). Forty patients were recruited into the trial.
These patients were randomly assigned to receive IFN-γ
(50μg/m2) subcutaneously three times per week (IFN-γ
group; n = 20) or betamethasone valerate topical cream
0.1%(betamethasonegroup;n = 20)everynightfor30days.
Patients were instructed by the study nurse to perform IFN-
γ injections by self and at bedtime. Topical betamethasone
was recommended to be applied on aﬀected skin area(s) one
hour before bedtime. They were also recommended to avoid
contact with allergens and other disease intensifying factors
and use acetaminophen in case of ﬂu-like symptoms.
The study protocol was approved by the Ethics Commit-
tee of the relevant University and written informed consent
was obtained from participants.
2.3. Eﬃcacy Measures. Extent and intensity of cutaneous
complications was evaluated using scoring atopic dermatitis
(SCORAD)index.ThisindexwasdevelopedbytheEuropean
Task Force on Atopic Dermatitis (ETFAD) in 1993 based on
a broad consensus by dermatologists [24].
SCORAD index consists of three parts: SCORAD-A:
extent of the disorder which is calculated based on the
rule of nines; SCORAD-B: intensity of the disorder which
comprises assessment and grading of six items as follows:
erythema, oedema/papulation, excoriations, licheniﬁcation,
oozing/crusts and dryness; and SCORAD-C: subjective
symptoms including pruritus and sleeplessness. Total SCO-
RAD score is calculated using the formula A/5 + 7B/2 + C.
The maximum scores of parts A, B,a n dC are 100, 18, and
20, respectively. Therefore, the SCORAD index would range
between0and103.ObjectiveSCORADisamodiﬁedformof
SCORAD index in which the subjective part—that appeared
to be a source of large variations—has been eliminated and
the concentration is focused on objective signs (extent and
intensity). The range of objective SCORAD lies between
0 and 83. Based on the Overall SCORAD and objective
SCORAD, the severity of disease could be classiﬁed into mild
(<15 for objective and <25 for overall SCORAD), moderate
(15–40 for objective and 25–50 for overall SCORAD), or
severe (≥40 for objective and ≥50 for overall SCORAD). In
the present study, overall and segmented SCORAD scores
were determined at baseline and at the end of trial.
2.4. Biochemical Measurements. A complete blood count
together with serum levels of Na, K, creatinine, blood
urea nitrogen (BUN), aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and alkaline phosphatase
(ALKP)wasdeterminedforpatientsusingroutinelaboratory
methods at baseline and after 4 weeks of treatment. In
addition, baseline and post trial serum concentrations of IL-
4, IL-6, IgE, and IFN-γ were determined in the IFN-γ group
to assess the impact of immunotherapy on these measures.The Scientiﬁc World Journal 3
2.5. Quality of Life Assessment. Dermatology Life Quality
Index (DLQI) was employed to evaluate the impact of
IFN-γ and topical betamethasone on patients’ quality of life.
DLQI is a simple, practical, and widely used index for the
assessment of health-related quality of life and has been
previously employed in Iranian population including sub-
jects with SM-induced chronic skin lesions [21]. In addition,
the validity and reliability of this index has been conﬁrmed
in an Iranian population [25]. DLQI questionnaire consists
of 10 questions under 6 headings: symptoms and feelings
(questions 1 and 2), daily activities (questions 3 and 4),
leisure (questions 5 and 6), work and school (question 7),
personal relationships (questions 8 and 9), and treatment
(question 10). Each question has a maximum score of 3 and
optionsof“verymuch”(scored3),“alot”(scored2),“alittle”
(scored 1), and “not at all” (scored 0). In addition, a “0”
score is allotted to “not relevant” response and unanswered
questions. DLQI total score is calculated by summing the
scores of all questions, resulting in a scoring range of 0–
30 in which higher scores are associated with more severe
impairments of life quality. DLQI scores of 0-1, 2–5, 6–10,
11–20, and 21–31 are equivalent to no, small, moderate, very
large, and extremely large eﬀects on patient’s quality of life,
respectively.
2.6. Statistical Analyses. Statistical analyses were performed
using SPSS software for Windows (version 16). Data were
expressed as mean ± SEM or number (%). Between and
within groups comparisons were made using independent
samples t-test and paired samples t-test, respectively. Cat-
egorical variables were compared using Fisher’s Exact test.
Bivariate correlations between diﬀerent parameters were
assessed using Pearson’s correlation coeﬃcients. A two-
sided P value of <0.05 was considered to be statistically
signiﬁcant.
3. Results
Fromthe40subjectswhowereinitially enteredthetrial, only
3 were dropped out of study in the betamethasone group due
to lack of compliance. Therefore, 37 subjects completed the
trial(n = 20 and 17 in the IFN-γ and betamethasone groups,
resp.;Figure 1)andwereincludedintheﬁnalanalyses.Drop-
out rate was not signiﬁcantly diﬀerent between the groups
(P>0.05).
3.1. Demographic Characteristics. T h eg r o u p sw e r ec o m p a -
rable regarding their age (38.90 ± 2.45 versus 39.12 ± 3.30
forIFN-γ andbetamethasonegroup,resp.)anddemographic
ﬁndings including weight, height, and BMI at baseline.
Likewise, there was no signiﬁcant diﬀerence between IFN-γ
and betamethasone groups in their vital signs including
pulse rate, respiratory rate, body temperature, and systolic
and diastolic blood pressure (P>0.05). Family histories
of allergic rhinitis (15.0% versus 0%) and atopic dermatitis
(15.8%versus0%) werealsocomparablebetween thegroups
(P>0.05).
3.2.SCORADIndex. Asreferredpreviously,extent,intensity,
and subjective symptoms of atopic dermatitis are reﬂected
in parts A, B,a n dC of the SCORAD index, respec-
tively. SCORAD-A and SCORAD-B scores were signiﬁcantly
decreased by the end of trial in both IFN-γ (P<0.001
for both SCORAD-A and SCORAD-B) and betamethasone
(P = 0.004 for SCORAD-A and P = 0.044 for SCORAD-
B). However, SCORAD-C score was decreased only in the
IFN-γ group (P<0.001) while no signiﬁcant change was
observed in the betamethasone group (P>0.05). There
were signiﬁcant reductions in overall SCORAD scores in
both groups (P<0.001 in the IFN-γ and P = 0.006 in the
betamethasone group). Objective SCORAD scores were also
signiﬁcantly decreased in both groups by the end of the trial
(P<0.001 in the IFN-γ and P = 0.006 in the betamethasone
group) (Table 1).
As for the magnitude of changes, treatment with IFN-
γ was associated with greater reductions in overall (P<
0.001), objective (P<0.001), and segmented (P<0.001)
SCORAD scores compared to betamethasone (Figure 2). At
baseline,bothgroupshadsevereADbasedontheirSCORAD
scores. At the end of trial, mean overall SCORAD score was
regressed from severe to mild in the IFN-γ group. However,
inspiteofsigniﬁcantreduction,meanoverallSCORADscore
did not regress to a less severe category in the betamethasone
group.
3.3. Quality of Life Index. DLQI scores were signiﬁcantly
decreased in both IFN-γ (P<0.001) and betamethasone
(P<0.001) groups by the end of trial, indicative of the
improvement of life quality. As for the magnitude of changes
in DLQI scores, no signiﬁcant diﬀerence was observed
between the groups (P>0.05) (Table 1).
3.4. Biochemical Parameters. Complete biochemistry proﬁle
was determined in the collected blood samples. No signif-
icant diﬀerence was found in the baseline as well as post-
trial levels of the assessed parameters, including serum Na,
K, AST, ALT, ALKP, Creatinine, BUN, CBC, and total and
direct billirubin, between the groups (P>0.05). Likewise,
none of these parameters were signiﬁcantly changed by the
e n do ft r i a li na n yo ft h eg r o u p s( P>0.05).
Administration of IFN-γ,5 0 μg/m2 three times weekly,
was associated with a signiﬁcant decrease in serum IgE
(28.93 ± 0.83 (baseline) versus 22.26 ± 0.75 (post-trial) at
baseline and at the end of trial, resp.; P<0.001) and IL-4
(64.21 ± 1.20 (baseline) versus 57.53 ± 1.34 (post-trial);
P<0.001) concentrations. In contrast no signiﬁcant change
was observed for serum IL-6 (0.61 ± 0.03 (baseline) versus
0.67 ± 0.05 (post-trial); P>0.05). Administration of IFN-γ
signiﬁcantly elevated mean serum IFN-γ by the end of trial
(41.23 ± 1.19 (baseline) versus 46.57 ± 1.49 (post-trial);
P = 0.013).
3.5. Adverse Events. Headache, vertigo, lethargy, blurred
vision, pruritus, myalgia, asthenia, and diarrhea were the
adverse eﬀects that were asked from both IFN-γ and
betamethasone groups. Interestingly, the incidence of none4 The Scientiﬁc World Journal
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Figure 1: Flowchart of the trial.
Table 1: Eﬀects of IFN-γ versus betamethasone 0.1% on the evaluated eﬃcacy measures.
IFN-γ
P value
Betamethasone 0.1%
P value
Pretrial Posttrial Pretrial Posttrial
DLQI 20.80 ± 0.88 8.20 ± 0.48 <0.001 21.88 ± 0.77 17.18 ± 1.28 <0.001
SCORAD-A 68.58 ± 4.47 29.05 ± 3.67 <0.001 44.15 ± 2.07 35.82 ± 2.35 0.004
SCORAD-B 11.35 ± 0.33 4.55 ± 0.34 <0.001 9.12 ± 0.57 8.29 ± 0.59 0.044
SCORAD-C 16.60 ± 1.03 6.10 ± 0.70 <0.001 15.94 ± 0.65 15.41 ± 0.84 >0.05
Objective SCORAD 53.44 ± 1.16 21.73 ± 1.77 <0.001 40.74 ± 1.89 36.19 ± 2.01 0.006
Overall SCORAD 71.44 ± 2.45 23.95 ± 1.78 <0.001 58.31 ± 1.88 51.60 ± 2.75 0.006
Values are expressed as mean ± SEM. DLQI: dermatology life quality index; SCORAD: scoring atopic dermatitis. SCORAD-A,- B,a n d- C denote extent,
intensity, and subjective symptoms of the disorder, respectively.
of these adverse events did signiﬁcantly diﬀer between the
groups(P>0.05)(Figure 3).Asidefromtheaforementioned
side eﬀects, the incidence of pain, swelling, redness, warmth,
itching, atrophy, utricaria, and nodule formation at the
injection site was speciﬁcally evaluated in the IFN-γ group
as summarized in Figure 4.
3.6. Bivariate Analysis. Bivariate correlations were assessed
between baseline and post-trial values of the eﬃcacy mea-
sures (DLQI, SCORAD-A, SCORAD-B, and SCORAD-C)
and serum concentrations of IL-4, IL-6, and IgE. Signif-
icantly positive correlations were found between baseline
DLQI and IL-6 (P = 0.01), baseline SCORAD-B and IL-4The Scientiﬁc World Journal 5
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Figure 2: Comparison of the magnitude of changes in SCORAD
and DLQI scores between IFN-γ and betamethasone groups.
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Figure 3: Frequency of evaluated adverse events in the study
groups.
(P = 0.001), and baseline SCORAD-C and IL-4 (P = 0.001).
On the other hand, signiﬁcantly negative correlations were
observed between baseline DLQI and IL-4 (P = 0.04), post-
trial DLQI and IL-6 (P = 0.02), and baseline SCORAD-B
and IL-6 (P = 0.01) (Table 2).
4. Discussion
The present study was designed to determine the eﬀect of
IFN-γ therapyonthequalityoflifeandseverityofsymptoms
in patients suﬀering from chronic SM-induced AD. The
secondary objective was to compare the eﬃcacy of IFN-γ
with that of topical betamethasone as the most commonly
administered medication for chronic SM-induced cutaneous
complications. The results indicated signiﬁcant improve-
ments in segmented and overall SCORAD as well as DLQI
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Figure 4: Frequency of injection site adverse events in the IFN-γ
group.
scores in both IFN-γ and betamethasone groups. Of note,
IFN-γ was found to be associated with greater improvement
in the evaluated eﬃcacy measures and well tolerated in
patients.
SM-induced dermatitis is accompanied by severe and
chronic pruritus in most cases. These pruritic symptoms
have been shown to aﬀect patients’ quality of life [21]. As
mentioned previously, chronic cutaneous complications of
SM intoxication could be categorized as a form of atopic
dermatitis. Unfortunately, no satisfactory treatment has yet
been introduced for AD. Although corticosteroids appear as
aneﬀectivetherapeuticapproach,theircontinuousandlong-
term application is associated with the incidence of several
side eﬀects [26], which may lead to the discontinuation of
drug. Application of other treatments such as cyclosporine is
also limited for the same reason [27].
Immune system is among the multiple organs that
are aﬀected by SM. Long-term SM-induced immunological
disturbances have been reported in intoxicated patients even
16–20 years post exposure [6, 28]. Severe pruritus and
resulting sleeping disorders were among the most important
complaints of patients at baseline. These complications,
assessed using SCORAD and DLQI indices, were improved
in both IFN-γ and betamethasone groups but the impact of
IFN-γ was signiﬁcantly superior to that of betamethasone.
The improvements in SCORAD index and quality of life
that were observed in the IFN-γ group were in line with
the signiﬁcant reductions in serum levels of IgE and IL-
4. Therefore, it is plausible that the beneﬁcial eﬀects of
IFN-γ are, at least in part, secondary to its well-known
immunomodulatory activities [29].
Treatment with IFN-γ has been previously shown to be
eﬃcacious in the alleviation of AD complications. However,
no study has to date evaluated the eﬃcacy of IFN-γ in
the treatment of SM-induced AD. In a previous survey
by Nuttall and colleagues [30], canine atopic dermatitis
was associated with overexpression of IL-4 mRNA and
reduced transcription of TGF-β compared to healthy skin.
In addition, signiﬁcantly higher levels of IFN-γ,T N F - α,
and IL-2 mRNA were seen in lesional atopic compared to
nonlesional atopic and healthy skin. In another investigation
by Reinhold et al. [18], treatment with IFN-γ for 6 weeks
caused marked clinical improvement in 8 out of the total6 The Scientiﬁc World Journal
Table 2: Bivariate analyses in the IFN-γ group.
IL-4 IL- 6 IgE
r P value r P value r P value
DLQI Pretrial −0.48 0.04 0.61 0.01 −0.27 0.28
Post-trial −0.06 0.81 −0.54 0.02 0.02 0.92
SCORAD-A Pretrial −0.18 0.48 0.47 0.05 −0.03 0.9
Post-trial −0.24 0.34 0.13 0.61 −0.29 0.24
SCORAD-B Pretrial 0.88 0.001 −0.56 0.01 0.32 0.2
Post-trial −0.06 0.81 0.24 0.35 −0.22 0.39
SCORAD-C Pretrial 0.74 0.01 −0.23 0.35 0.13 0.61
Post-trial −0.12 0.63 0.04 0.87 −0.14 0.57
DLQI: dermatology life quality index; SCORAD: scoring atopic dermatitis. SCORAD-A,- B,a n d- C denote extent, intensity, and subjective symptoms of the
disorder, respectively.
of 14 treated patients. Haniﬁn et al. [19] have reported that
treatment with IFN-γ f o r1 2w e e k sw a ss a f ea n de ﬀective in
reducing inﬂammation, clinical symptoms, and eosinophilia
in severe atopic dermatitis. In another comprehensive study
by Stevens and colleagues [20], long-term eﬀects of IFN-γ
therapy were assessed in patients with atopic dermatitis
for a period of 2 years. The results indicated that long-
term administration of IFN-γ is associated with signiﬁcant
reductions in disease extent and clinical severity scores for
pruritus, erythema, edema, excoriations, dryness, licheniﬁ-
cation, and other atopic symptoms. The eﬃcacy of 4-week
recombinant IFN-γ has also been evaluated against topical
diphenhydramine in the treatment of canine AD [31]. The
ﬁndings were indicative of the signiﬁcantly higher eﬃcacy of
IFN-γ comparedtodiphenhydramineintheimprovementof
pruritus, erythema, excoriation, and alopecia.
Aside from eﬃcacy,anotherimportantfactorthatshould
be considered for an ideal AD therapy is safety issue.
Interestingly, the incidence of none of the evaluated side
eﬀects did signiﬁcantly diﬀer between the groups. This is
especially important when considering that the comparison
was between a parenteral and a topically administered drug.
Asfortheinjectionsitereactions,theincidenceofsideeﬀects
was generally low except for pain and swelling. However,
none of the side eﬀects at the site of injection led to the
discontinuation of IFN-γ. In addition, no adverse eﬀect
was observed from IFN-γ on blood biochemical parameters
including markers of hematological, renal, and hepatic
function. These results are consistent with those obtained by
Stevens et al., who indicated that IFN-γ is well tolerated over
a long-term (2 years) period [20].
Along with the disturbances in the immune system,
sulfur mustard induces barrier damage through its vari-
ous apoptotic, necrotizing, and inﬂammatory eﬀects that
all impair skin permeability, connectivity, and biophysical
properties. In addition, sulfur mustard alkylates extracellular
matrix proteins, thereby impairing the interaction of basal
keratinocytes to matrix proteins and their adherence to
basement membrane [3, 32–34]. These eﬀects of sulfur
mustard are particularly important in stratum corneum
which is the main barrier against water loss. In a recent
study, transepidermal water loss has been shown to be higher
in patients with chronic mustard-induced skin lesions com-
pared to healthy subjects [35]. On the other hand, the same
patients have been frequently reported to complain from
xerosis (a consequence of damage to the skin’s hydrolipidic
barrier) [8, 12–14]. Therefore, more research is needed to
better understand the impact of immunotherapy with IFN-γ
on the barrier function of skin in SM-intoxicated patients.
To sum up, the present research provided the ﬁrst
evidence on the eﬃcacy of IFN-γ therapy in SM-induced
AD. Promising improvements in quality life and clinical
symptomsthatwereobservedinthepresentstudysuggestthe
application of IFN-γ as an eﬀective therapy for the manage-
ment of SM-induced chronic skin complications. Since the
present trial was not blinded, it would be helpful to conﬁrm
the eﬀectiveness of IFN-γ in a future double-blind study. It
is also recommended that further research be undertaken to
elucidate the impact of immunotherapy with IFN-γ on other
immune and inﬂammatory biomarkers which are altered in
AD. Finally, future trials are warranted to assess the eﬃcacy
of IFN-γ against other chronic complications of SM.
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